berythromycin
Modify Date: 2024-01-02 20:12:09
berythromycin structure
|
Common Name | berythromycin | ||
|---|---|---|---|---|
| CAS Number | 527-75-3 | Molecular Weight | 717.927 | |
| Density | 1.2±0.1 g/cm3 | Boiling Point | 807.6±65.0 °C at 760 mmHg | |
| Molecular Formula | C37H67NO12 | Melting Point | 168-170ºC (dec) | |
| MSDS | N/A | Flash Point | 442.2±34.3 °C | |
| Symbol |
GHS07 |
Signal Word | Warning | |
| Name | erythromycin B |
|---|---|
| Synonym | More Synonyms |
| Density | 1.2±0.1 g/cm3 |
|---|---|
| Boiling Point | 807.6±65.0 °C at 760 mmHg |
| Melting Point | 168-170ºC (dec) |
| Molecular Formula | C37H67NO12 |
| Molecular Weight | 717.927 |
| Flash Point | 442.2±34.3 °C |
| Exact Mass | 717.466309 |
| PSA | 173.68000 |
| LogP | 3.12 |
| Vapour Pressure | 0.0±6.5 mmHg at 25°C |
| Index of Refraction | 1.527 |
| Storage condition | 20°C |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| Precursor 2 | |
|---|---|
| DownStream 0 | |
![(2R,3R,4R,6R,7S,8S,9S,10S,11R)-11-[(benzyloxy)methoxy]-4-[(tert-butyldimethylsilyl)oxy]-3-[(4-methoxybenzyl)oxy]-2,4,6,8,10-pentamethyl-7,9-{[(R)-2,4,6-trimethylbenzylidene]dioxy}tridecanal Structure](https://www.chemsrc.com/caspic/090/188786-14-3.png)
CAS#:188786-14-3![(2S,3R,4R,6R,8R,9S,10R,11R)-11-[(benzyloxy)methoxy]-1,4-bis[(tert-butyldimethylsilyl)oxy]-9-hydroxy-3-[(4-methoxybenzyl)oxy]-2,4,6,8,10-pentamethyltridecan-7-one Structure](https://www.chemsrc.com/caspic/259/188786-05-2.png)
CAS#:188786-05-2|
A simple and rapid confirmatory assay for analyzing antibiotic residues of the macrolide class and lincomycin in bovine milk and yoghurt: hot water extraction followed by liquid chromatography/tandem mass spectrometry.
Rapid Commun. Mass Spectrom. 21(2) , 237-46, (2007) A rapid and simple sample preparation procedure for determining residues of antibiotics of the class of macrolides and lincomycin in whole milk and yoghurt by liquid chromatography/tandem mass spectro... |
|
|
Acid-catalyzed degradation of clarithromycin and erythromycin B: a comparative study using NMR spectroscopy.
J. Med. Chem. 43(3) , 467-74, (2000) One of the major drawbacks in the use of the antibiotic erythromycin A is its extreme acid sensitivity, leading to degradation in the stomach following oral administration. The modern derivative clari... |
|
|
An abiotic strategy for the enantioselective synthesis of erythromycin B.
Angew. Chem. Int. Ed. Engl. 42(28) , 3278-81, (2003)
|
| 12-Deoxyerythromycin |
| (3R,4S,5S,6R,7R,9R,11R,12S,13R,14R)-6-{[(2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-14-ethyl-7,12-dihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy}-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione |
| berythromycinum |
| berythromycin |
| beritromicina |
| berythromycine |
| (3R,4S,6R,7R,9R,11R,12S,13R,14R)-6-[4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12-dihydroxy-4-(5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl)oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione |
| erythromycin B |
| (3R,4S,5S,6R,7R,9R,11R,12S,13R,14R)-6-{[(2S,3R,4S,6R)-4-(Dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-14-ethyl-7,12-dihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy}-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione (non-preferred name) |
| berythromycinum [INN_la] |
| Erythromycin Impurity 2 |